5 terminated. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 5 |
| Phase 2 | 1 | Terminated 1 |
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma, Non-Hodgkin (4) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
Rituximab (4) · Bendamustine Hydrochloride (2) · Azacitidine (1) · Cyclophosphamide (1) · Doxorubicin (1) · Gemcitabine (1) · Oxaliplatin (1) · Prednisone (1) · Vincristine (1) · avelumab (1) · ibritumomab tiuxetan (1) · obinutuzumab (1) · ublituximab (1) · umbralisib (1) · utomilumab (1)
Hoffmann-La Roche (1) · JHL Biotech, Inc. (1) · Pfizer (1) · Spectrum Pharmaceuticals, Inc (1) · TG Therapeutics, Inc. (1)
Australia (4) · Italy (4) · Spain (4) · United Kingdom (4) · United States (4) · Poland (3) · South Korea (3) · Austria (2) · Belgium (2) · Canada (2) · China (2) · Israel (2) · Slovakia (2) · Argentina (1) · Brazil (1)
Jun Zhu, MD/PhD (1) · Owen A O'Connor, MD, PhD (1)
PMID 30341058, PMID 30617197, PMID 30770362, PMID 31053601, PMID 32505213, PMID 33054054, PMID 33651099, PMID 33683917, PMID 34323957, PMID 34323958, PMID 34687398, PMID 35962459, PMID 37702406, PMID 38498084, PMID 38843483, PMID 39962481, PMID 42699559
2016 (1)